James D. Chambers

Tufts University — United States

Economics, Econometrics and Finance · Social Sciences

25h-index1.8kcitations165works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Health Systems, Economic Evaluations, Quality of Life(103), Pharmaceutical Economics and Policy(60), Healthcare Policy and Management(32), Economic and Financial Impacts of Cancer(21), Healthcare cost, quality, practices(21)

Publications164 total

U.S. health plan coverage of Neuromuscular Disease Therapies: An assessment of policy availability and restrictions
Journal of Neuromuscular Diseases·2025Open Access
Real-World Clinical Oncology Outcomes Associated with the Accelerated Approval Pathway
Cancer Research Communications·2025Open Access
The unintended consequences of the inflation reduction act on biosimilar market incentives and Medicare savings
Health Affairs Scholar·2025Open Access
Variation in US Commercial Health Plan Coverage Restrictions for Cell and Gene Therapies
JAMA·2025Open Access
What drug characteristics explain the wide range of manufacturer rebates?
Health Affairs Scholar·2025Open Access
PT21 US Commercial Health Plan Coverage of Oncology Therapies: 2017 - 2024
Value in Health·2025
HTA7 Use of Health Technology Assessments in Specialty Drug Coverage Decisions by U.S. Commercial Health Plans
Value in Health·2025
HPR121 What Drug Characteristics Explain the Wide range of Manufacturer Rebates?
Value in Health·2025
CO106 Use of Clinical Outcome Assessments in Specialty Drug Coverage Policies
Value in Health·2025
Drug Coverage Policies And Clinical Guidelines Alignment: Most Coverage Decisions Include Additional Restrictions
Health Affairs·2025· 3 cited
Incidental appendiceal mucocele discovery: A case series and literature review
International Journal of Surgery Case Reports·2025· 2 citedOpen Access
Assessing variation in US payer coverage of anti–vascular endothelial growth factor therapies for the treatment of age-related macular degeneration, diabetic retinopathy, and diabetic macular edema
Journal of Managed Care & Specialty Pharmacy·2025· 1 citedOpen Access
An analysis of US net cancer drug launch prices and clinical efficacy and certainty of evidence from 2008 to 2022
Health Affairs Scholar·2025Open Access
Use of health technology assessments in specialty drug coverage decisions by US commercial health plans.
PubMed·2025· 1 citedOpen Access
Should Mesh Plug Use Be Discontinued in Hernia Repair Practices?
Cureus·2024Open Access
Small-Molecule Drugs Offer Comparable Health Benefits To Biologics At Lower Costs
Health Affairs·2024· 3 cited
Optimal Surgical Approaches for Incidentally Discovered Ruptured Mucinous Appendiceal Neoplasms
Cureus·2024· 2 citedOpen Access
Are Drug Novelty Characteristics Associated With Greater Health Benefits?
Applied Health Economics and Health Policy·2024
US Commercial Plans Increase Choice Of Biosimilar And Originator Products; Market Net Prices Decrease
Health Affairs·2024· 1 cited
Managing locally advanced GIST complicated by perforation: A case report and comprehensive review
Radiology Case Reports·2024Open Access
page 1 of 9Next →

Frequent Co-authors

Peter J. Neumann(34), Joshua T. Cohen(8), David D. Kim(5), Colby Wilkinson(5), Teja Thorat(5), Matthew Chenoweth(5), Elle Pope(4), Martin Buxton(4), Junhee Pyo(4), Nikoletta M. Margaretos(4), Kathryn A. Phillips(3), Patricia A. Deverka(3), Michael P. Douglas(3), Ari D. Panzer(3), J. Edgar Anderson(3), Prasun Subedi(2), Neal R. Barshes(2), Michael Belkin(2), Jennifer S. Graff(2), Julia R. Trosman(2)